Emergence of meningococci with reduced susceptibility to third-generation cephalosporins

Reduced susceptibility to penicillin G in Neisseria meningitidis is mainly due to alterations in PBP2 encoded by the penA gene. However, this phenotype was not associated with reduced susceptibility to third-generation cephalosporins (C3Gs). We aimed to study the emergence of meningococci with reduc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2017-01, Vol.72 (1), p.95-98
Main Authors: Deghmane, Ala-Eddine, Hong, Eva, Taha, Muhamed-Kheir
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Bacteriology
Cephalosporin Resistance
Cephalosporins - pharmacology
France
Genes, Bacterial
Genotype
Humans
Life Sciences
Meningococcal Infections - microbiology
Microbial Sensitivity Tests
Microbiology and Parasitology
Multilocus Sequence Typing
Neisseria meningitidis - classification
Neisseria meningitidis - drug effects
Neisseria meningitidis - genetics
Neisseria meningitidis - isolation & purification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reduced susceptibility to penicillin G in Neisseria meningitidis is mainly due to alterations in PBP2 encoded by the penA gene. However, this phenotype was not associated with reduced susceptibility to third-generation cephalosporins (C3Gs). We aimed to study the emergence of meningococci with reduced susceptibility to C3Gs (MIC >0.06 mg/L) in France since 2012. Invasive meningococcal isolates were typed by MLST and penA sequencing and their antibiotic susceptibility was tested. Isolates with reduced susceptibility to C3Gs represented 2% of all invasive isolates from 2012-15, but were absent before. They harboured a new penA allele, penA327, that was also detected in isolates from urethritis cases and in gonococci. Surveillance of these isolates should be enhanced as they may jeopardize the use of C3Gs in the management of invasive meningococcal disease.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkw400